Declining susceptibilities of gram-negative bacteria to the fluoroquinolones: Effects on pharmacokinetics, pharmacodynamics, and clinical outcomes
- 1 November 2012
- journal article
- review article
- Published by Oxford University Press (OUP) in American Journal of Health-System Pharmacy
- Vol. 69 (21) , 1863-1870
Abstract
Purpose Published evidence of rising gram-negative bacterial resistance to fluoroquinolone therapy is reviewed, with a focus on the potential need for revising pharmacokinetic–pharmacodynamic (PK–PD) targets in order to maintain acceptable clinical outcomes. Summary With a more than threefold increase in fluoroquinolone use among U.S. adults since the introduction of second- and third-generation (i.e., “respiratory”) fluoroquinolones 15 years ago, surveillance data indicate a decline in some gram-negative organisms' susceptibility to this antimicrobial class. These trends have raised concerns that the need to attain higher organism-specific minimum inhibitory concentrations (MICs) may lead to worse patient outcomes, even when MIC values are below current established “clinical breakpoints” for fluoroquinolone susceptibility. A growing body of evidence from PK–PD studies suggests that current fluoroquinolone dosing regimens are no longer adequate to achieve validated PK–PD targets. For example, a Monte Carlo simulation using PK data from U.S. hospitals showed decreasing rates of response to standard ciprofloxacin and levofloxacin i.v. dosing regimens among patients treated for infections with Escherichia coli and Klebsiella species. These findings suggest that currently accepted PK–PD targets may need to be revised for certain patient populations, including patients with bloodstream infections (BSIs). More research is needed to confirm the appropriateness of adjusting clinical breakpoints and other strategies to combat rising fluoroquinolone resistance. Conclusion The use of the fluoroquinolones has markedly increased since the introduction of the respiratory fluoroquinolones. Surveillance data and PK–PD studies have raised concerns about suboptimal patient outcomes with the use of fluoroquinolones for some gram-negative infections, particularly BSIs. PK–PD goals and clinical breakpoints may need to be revised for these infections.Keywords
This publication has 36 references indexed in Scilit:
- Fluoroquinolones in Community-Acquired PneumoniaDrugs, 2011
- Support for higher ciprofloxacin AUC24/MIC targets in treating Enterobacteriaceae bloodstream infectionJournal of Antimicrobial Chemotherapy, 2010
- Hospital-Acquired Infections Due to Gram-Negative BacteriaNew England Journal of Medicine, 2010
- Summary trends for the Meropenem Yearly Susceptibility Test Information Collection Program: a 10-year experience in the United States (1999–2008)Diagnostic Microbiology and Infectious Disease, 2009
- Effect of Differences in MIC Values on Clinical Outcomes in Patients with Bloodstream Infections Caused by Gram-Negative Organisms Treated with LevofloxacinAntimicrobial Agents and Chemotherapy, 2009
- The Quinolones: Past, Present, and FutureClinical Infectious Diseases, 2005
- Fluoroquinolone prescribing in the United States: 1995 to 2002The American Journal of Medicine, 2005
- Levofloxacin: update and perspectives on one of the original ‘respiratory quinolones’Expert Review of Anti-infective Therapy, 2003
- Pharmacodynamics of LevofloxacinJAMA, 1998
- Pharmacodynamics of intravenous ciprofloxacin in seriously ill patientsAntimicrobial Agents and Chemotherapy, 1993